Citius Oncology (CTOR) Competitors $1.88 +0.01 (+0.53%) Closing price 04:00 PM EasternExtended Trading$1.90 +0.02 (+0.80%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CTOR vs. RLAY, RAPP, KROS, SIGA, RZLT, MRVI, TRML, XNCR, GOSS, and MGTXShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Relay Therapeutics (RLAY), Rapport Therapeutics (RAPP), Keros Therapeutics (KROS), Siga Technologies (SIGA), Rezolute (RZLT), Maravai LifeSciences (MRVI), Tourmaline Bio (TRML), Xencor (XNCR), Gossamer Bio (GOSS), and MeiraGTx (MGTX). These companies are all part of the "pharmaceutical products" industry. Citius Oncology vs. Its Competitors Relay Therapeutics Rapport Therapeutics Keros Therapeutics Siga Technologies Rezolute Maravai LifeSciences Tourmaline Bio Xencor Gossamer Bio MeiraGTx Relay Therapeutics (NASDAQ:RLAY) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability. Do insiders & institutionals have more ownership in RLAY or CTOR? 97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 4.9% of Relay Therapeutics shares are owned by insiders. Comparatively, 4.6% of Citius Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer RLAY or CTOR? Relay Therapeutics presently has a consensus target price of $17.50, suggesting a potential upside of 324.76%. Citius Oncology has a consensus target price of $3.00, suggesting a potential upside of 59.57%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relay Therapeutics is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92Citius Oncology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, RLAY or CTOR? Relay Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Citius Oncology has a beta of 2.99, meaning that its stock price is 199% more volatile than the S&P 500. Which has preferable valuation & earnings, RLAY or CTOR? Citius Oncology has lower revenue, but higher earnings than Relay Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelay Therapeutics$10.01M70.96-$337.71M-$1.95-2.11Citius OncologyN/AN/AN/AN/AN/A Does the media prefer RLAY or CTOR? In the previous week, Relay Therapeutics had 10 more articles in the media than Citius Oncology. MarketBeat recorded 10 mentions for Relay Therapeutics and 0 mentions for Citius Oncology. Relay Therapeutics' average media sentiment score of 0.86 beat Citius Oncology's score of 0.00 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Relay Therapeutics Positive Citius Oncology Neutral Is RLAY or CTOR more profitable? Relay Therapeutics' return on equity of -41.49% beat Citius Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Relay TherapeuticsN/A -41.49% -37.43% Citius Oncology N/A -51.93%-22.17% SummaryRelay Therapeutics beats Citius Oncology on 10 of the 12 factors compared between the two stocks. Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$147.34M$3.16B$5.77B$9.93BDividend YieldN/A2.28%6.67%4.52%P/E RatioN/A21.1075.6026.68Price / SalesN/A467.69555.18213.69Price / CashN/A45.1137.1158.92Price / Book2.949.8611.446.09Net IncomeN/A-$53.47M$3.28B$266.14M7 Day Performance-13.36%2.89%0.84%0.27%1 Month Performance3.87%8.62%7.15%4.13%1 Year PerformanceN/A13.69%59.65%23.93% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius Oncology0.9716 of 5 stars$1.88+0.5%$3.00+59.6%+8.1%$147.34MN/A0.00N/AGap DownRLAYRelay Therapeutics2.3964 of 5 stars$3.71+3.3%$17.08+360.8%-37.0%$642.23M$10.01M-1.91330News CoverageAnalyst ForecastRAPPRapport Therapeutics2.4874 of 5 stars$17.33-1.7%$29.50+70.3%-27.6%$638.39MN/A-7.00N/ANews CoverageKROSKeros Therapeutics3.3714 of 5 stars$15.67+3.0%$30.00+91.4%-70.6%$637.82M$3.55M50.65100News CoveragePositive NewsSIGASiga Technologies2.347 of 5 stars$8.74+4.2%N/A+8.2%$627.52M$138.72M7.7540News CoverageOptions VolumeRZLTRezolute3.1716 of 5 stars$7.23+1.5%$12.50+72.9%+57.0%$626.31MN/A-6.2640News CoveragePositive NewsAnalyst ForecastMRVIMaravai LifeSciences3.6953 of 5 stars$2.38-1.9%$5.22+119.7%-71.1%$611.59M$259.18M-1.76610Positive NewsOptions VolumeTRMLTourmaline Bio2.4166 of 5 stars$23.66+1.1%$50.14+111.9%+53.5%$607.95MN/A-6.9044Positive NewsGap UpXNCRXencor3.8309 of 5 stars$8.56+5.2%$23.71+177.2%-49.7%$607.29M$110.49M-3.55280News CoverageAnalyst ForecastGOSSGossamer Bio4.0144 of 5 stars$2.65+7.1%$8.50+221.4%+192.3%$605.97M$114.70M-4.30180News CoverageMGTXMeiraGTx4.5112 of 5 stars$7.44+1.8%$24.00+222.8%+95.9%$600.56M$33.28M-3.66300Positive News Related Companies and Tools Related Companies Relay Therapeutics Competitors Rapport Therapeutics Competitors Keros Therapeutics Competitors Siga Technologies Competitors Rezolute Competitors Maravai LifeSciences Competitors Tourmaline Bio Competitors Xencor Competitors Gossamer Bio Competitors MeiraGTx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTOR) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTOR Stock Alerts